Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

July 19, 2018 0

Novartis’ (NVS) financials results exceeded analysts’ expectations. The firm’s research institutions’ strategy, well-designed structure, plans for …

Once again, we say, CRISPR is here to stay

July 18, 2018 0

A Miracle-Like Gene-Editing That People will Sooner or Later Recognize. The Wellcome Sanger Institute’s new findings …

$Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women$

Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women

July 13, 2018 0

The BLA Includes Data from More Than 11,000 Patients Amgen (AMGN) and UCB (Euronext Brussels: UCB) …

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

July 5, 2018 0

The New England Journal of Medicine (NEJM) published results from the CELESTIAL phase 3 pivotal trial …

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

July 3, 2018 0

Finally, we are hearing what we were constantly expecting to hear coming out of Compugen’s (CGEN) …

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Why Vertex added over $20 to its stock price today

June 29, 2018 0

Health Canada Approves PrSYMDEKO™ For People Ages 12 and Older With Certain CFTR Gene Mutations Vertex …

The FDA approved a combination of two products. Both belong to Array Biopharma

June 28, 2018 0

The FDA approved Array BioPharma’s (ARRY) products Braftovi™ capsules in combination with Mektovi® tablets for unresectable or …

Exploring two clinical-stage firms with new, different approaches to treatments

June 27, 2018 0

SOPHIRIS BIO AND NANOBIOTIX SOPHIRIS BIO Sophiris Bio (SPHS) has a product called Topsalysin (PRX302) in …

Our outperforming firms and more

June 25, 2018 0

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology …

Incyte’s promising trial results and its plans to accelerate its future growth

June 21, 2018 0

Incyte (INCY) announced positive topline results from its pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi®) …

Reasons for RegenxBio’s outperformance and some other Prohost big winners

June 20, 2018 0

On May 25, in Prohost Letter Issue #421, we wrote about RegenxBio (RGNX), which from behind …

Finally! CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences are granted the patent they have long been looking for

June 20, 2018 0

CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences, Inc., announced the news about the granted U.S. Patent No. …

Sarepta announced successful results from a preliminary trial for Duchenne Muscular Dystrophy

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Novartis Pleased the Market with Its Q2 Financial Results and Pleased Us with Its Great Scientific Achievements. See Also: The Role AveXis and RegenxBio are Playing Towards the Future Success of Novartis

Once again, we say, CRISPR is here to stay

Amgen and UCB resubmit BLA to the FDA for the approval of Evenity™ to prevent or heal Osteoporosis bone fracture in post-menopausal women

Stories about research, clinical trials results and an FDA ruling

Exelixis liver cancer results are gratifying, so do not worry if some pretend they do not like them

The FDA Clears Compugen’s and Bayer’s IND Application for Their Checkpoint Inhibitor Immunotherapy Product

Finding reasons for underperforming stocks

Why Vertex added over $20 to its stock price today

The FDA approved a combination of two products. Both belong to Array Biopharma

Exploring two clinical-stage firms with new, different approaches to treatments

Our outperforming firms and more

Incyte’s promising trial results and its plans to accelerate its future growth

Reasons for RegenxBio’s outperformance and some other Prohost big winners

Finally! CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences are granted the patent they have long been looking for

Sarepta announced successful results from a preliminary trial for Duchenne Muscular Dystrophy

Good News, Bad News & Comebacks. See Also: ASCO Results

Why FDA approval of Agilent Technologies’ Assay is important to cervical cancer patients

The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma (PMBCL)

CRISPR Editing and the two published studies

New stock selection and re-evaluation